WuXi PharmaTech, China's largest CRO, is counting on the burgeoning drug development market in its home country to deliver a big 2013, stretching its annual revenue guidance after another quarterly boost.
Quintiles is back on the buyer's block for the first time since going public, agreeing to scoop up oncology-focused CRO Novella Clinical for an undisclosed sum.
Bristol-Myers Squibb is calling it quits on a depression drug it was working on with Albany Molecular Research, and investors sent the contractor's shares into a plunge as its CEO preached patience.
Covance has launched a managed markets service platform designed to help its biopharma and medical device clients deal with managed care organizations, group purchasing outfits, federal and state programs and wholesalers.
CRO Icon has signed a deal with the National Taiwan University Hospital, lending its weight in clinical research to help make local trials faster and more reliable.
Taiwanese contract manufacturer ScinoPharm and Chinese CRO Sundia MediTech are pooling their resources to cash in on the demand for outsourced services in China.
Parexel turned in another quarter of double-digit sales growth, riding increases in IT and consulting revenue to a huge year-over-year jump in profits.
AMRI watched a spike in costs erode its solid second-quarter sales, but the the contract drugmaker still believes it can churn out an annual profit and boost its revenue.
CRO inVentiv Health is teaming up with Oncobiologics to develop biosimilars of some of world's top-selling treatments, signing up to helm clinical trials and help get the knockoffs on the market.
Clinipace has struck a deal with Finland's Medfiles, allowing the North Carolina CRO to offer its clients services across the Nordics and Baltic countries.
As more and more eyes turn toward Japan for clinical trials, INC Research is setting up two outposts in the country, building off years of local partnerships and going it alone in the growing market.
Preclinical specialist Charles River Labs posted solid revenue growth despite a tough market for early-phase services, but a spike in charges pulled down net income on an otherwise strong second quarter.
In its first earnings release since going public back in May, CRO giant Quintiles turned in a so-so quarter, as flat service revenue coupled with the costs of settling debts dragged down net income.
CRO Covance rode a rise in revenue to $41 million in net profit in the second quarter, beating out a year-ago loss and weathering the sliding demand for early-stage outsourcing.
A month removed from its $1.3 billion agreement to buy PRA, KKR has signed a deal to acquire ReSearch Pharmaceutical Services, planning to merge the two CROs once the transactions close.
Psi, a global CRO out of Switzerland, has expanded into South Africa, touting the nation's diversity and regulatory environment as ideal for patient recruitment and drug development.
More and more companies are eyeing antibody-drug conjugate technology as a path to success in drug development, and Indian contract manufacturer Piramal is spending $2.5 million to expand its ability to supply the in-demand formulation.
Ascendancy Healthcare has tapped Quintiles to help it capitalize on China's booming pharmaceutical market, asking the world's largest CRO to help it choose, develop and market in-licensed therapies.
Dublin's Icon nailed down another strong sales quarter, growing revenue 21% and increasing its full-year expectations.
Clinical Research Advantage is stretching out its business model, buying up Comprehensive Clinical Development's late-stage trials unit and reaching into central nervous system studies.